312 related articles for article (PubMed ID: 37892997)
1. Interleukin-6 in Hepatocellular Carcinoma: A Dualistic Point of View.
Nenu I; Toadere TM; Topor I; Țichindeleanu A; Bondor DA; Trella ȘE; Sparchez Z; Filip GA
Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37892997
[TBL] [Abstract][Full Text] [Related]
2. Bibliometric study of immunotherapy for hepatocellular carcinoma.
Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
[TBL] [Abstract][Full Text] [Related]
3. Ligustilide counteracts carcinogenesis and hepatocellular carcinoma cell-evoked macrophage M2 polarization by regulating yes-associated protein-mediated interleukin-6 secretion.
Yang J; Xing Z
Exp Biol Med (Maywood); 2021 Sep; 246(17):1928-1937. PubMed ID: 34053234
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted roles of lymphatic and blood endothelial cells in the tumor microenvironment of hepatocellular carcinoma: A comprehensive review.
Li JJ; Mao JX; Zhong HX; Zhao YY; Teng F; Lu XY; Zhu LY; Gao Y; Fu H; Guo WY
World J Hepatol; 2024 Apr; 16(4):537-549. PubMed ID: 38689749
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
Yao C; Wu S; Kong J; Sun Y; Bai Y; Zhu R; Li Z; Sun W; Zheng L
Cancer Biol Med; 2023 Jan; 20(1):25-43. PubMed ID: 36647777
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in understanding mitokines as diagnostic and therapeutic targets in hepatocellular carcinoma.
Wang J; Luo LZ; Liang DM; Guo C; Huang ZH; Jian XH; Wen J
World J Clin Cases; 2023 Aug; 11(23):5416-5429. PubMed ID: 37637689
[TBL] [Abstract][Full Text] [Related]
8. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
9. Exploring neutrophil functionality in breast cancer progression: A review.
Obeagu EI; Obeagu GU
Medicine (Baltimore); 2024 Mar; 103(13):e37654. PubMed ID: 38552040
[TBL] [Abstract][Full Text] [Related]
10. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
[TBL] [Abstract][Full Text] [Related]
11. Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment.
Wang W; Wu J; Ji M; Wu C
J Transl Med; 2020 Dec; 18(1):477. PubMed ID: 33308251
[TBL] [Abstract][Full Text] [Related]
12. Identification of interleukin-16 production on tumor aggravation in hepatocellular carcinoma by a proteomics approach.
Takeba Y; Ohta Y; Ootaki M; Kobayashi T; Kida K; Watanabe M; Koizumi S; Otsubo T; Iiri T; Matsumoto N
Tumour Biol; 2021; 43(1):309-325. PubMed ID: 34897107
[TBL] [Abstract][Full Text] [Related]
13. Unveiling the Role of Tumor-Infiltrating T Cells and Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review.
Chen X; Liu X; Du S
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894413
[TBL] [Abstract][Full Text] [Related]
14. The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications.
Gungor MZ; Uysal M; Senturk S
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205692
[TBL] [Abstract][Full Text] [Related]
15. Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches.
Arvanitakis K; Papadakos SP; Lekakis V; Koufakis T; Lempesis IG; Papantoniou E; Kalopitas G; Georgakopoulou VE; Stergiou IE; Theocharis S; Germanidis G
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834153
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.
Hilmi M; Neuzillet C; Calderaro J; Lafdil F; Pawlotsky JM; Rousseau B
J Immunother Cancer; 2019 Nov; 7(1):333. PubMed ID: 31783782
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions.
Wazir H; Abid M; Essani B; Saeed H; Ahmad Khan M; Nasrullah F; Qadeer U; Khalid A; Varrassi G; Muzammil MA; Maryam A; Syed ARS; Shah AA; Kinger S; Ullah F
Cureus; 2023 Dec; 15(12):e49920. PubMed ID: 38174191
[TBL] [Abstract][Full Text] [Related]
18. IL-37b suppresses epithelial mesenchymal transition in hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling.
Pu XY; Zheng DF; Shen A; Gu HT; Wei XF; Mou T; Zhang JB; Liu R
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):408-415. PubMed ID: 30201411
[TBL] [Abstract][Full Text] [Related]
19. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma.
Moran DM; Mayes N; Koniaris LG; Cahill PA; McKillop IH
Liver Int; 2005 Apr; 25(2):445-57. PubMed ID: 15780071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
